引用本文:
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2330次   下载 1360 本文二维码信息
码上扫一扫!
分享到: 微信 更多
替吉奥联合奥沙利铂或奈达铂同步放疗治疗局部进展期食管鳞癌的临床观察
仇建波,卢央芳,陆意,黄闽杰,张占春
作者单位
仇建波 宁波市医疗中心李惠利医院肿瘤放疗科 
卢央芳 宁波市医疗中心李惠利医院肿瘤放疗科 
陆意 宁波市医疗中心李惠利医院肿瘤放疗科 
黄闽杰 宁波市医疗中心李惠利医院肿瘤放疗科 
张占春 宁波市医疗中心李惠利医院肿瘤放疗科 
摘要:
目的 比较替吉奥联合奥沙利铂(OXA)或奈达铂(NDP)同步放疗治疗局部进展期食管鳞癌的临床疗效和相关不 良反应。方法 选择局部进展期食管鳞癌患者72 例,随机分为观察组(38 例)和对照组(34 例),两组均采用同步放化疗。观察组采用替吉奥联合OXA 治疗,OXA 剂量为130mg/m2,静脉滴注,d1,替吉奥40mg/m2,早晚各1 次口服,d1~14。对照组采用NDP,剂量为80mg/m2,静脉滴注,d1,其余治疗方法同观察组。两组患者放、化疗同时开始,3周为1 个疗程,共化疗2个疗程。比较两组患者治疗后的临床疗效、生存期及不良反应情况。结果 观察组和对照组近期总有效率分别为81.6%和82.4%,两组比较无统计学差异(P>0.05);观察组和对照组患者1、2、3 年生存率分别为86.8%、57.9%、28.9%和85.3%、55.9%、29.4%,两组比较均无统计学差异(均P >0.05)。观察组患者外周神经毒性反应发生率高于对照组(P<0.05);而在骨髓抑制、放射性食管炎及放射性肺炎等其他方面的不良反应发生率均类似于对照组,两组比较均无统计学差异(均P>0.05)。结论在局部进展期食管癌同步放化疗中,替吉奥联合OXA 方案与替吉奥联合NDP 方案患者的近期有效率与远期生存率相当,有效性和耐受性都较好,值得进一步 前瞻性探索。
关键词:  食管鳞癌  同步放化疗  替吉奥  奥沙利铂  奈达铂
DOI:
分类号:
基金项目:宁波市科技创新团队基金
Concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: S-1 plus oxaliplatin vs S-1 plusnedaplatin
CHOU Jianbo,LU Yangfang,LU Yi,HUANG Minjie,ZHANG Zhanchun
Abstract:
Objective To compare the clinical efficacy and adverse reactions of S-1 plus oxaliplatin or nedaplatin in concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma(ESCC). Methods Seventy two patients with locally advanced ESCC were randomly assigned in to two groups: 38 patients in observation group received S-1 plus oxaliplatin (oxaliplatin 130mg/m2, intravenous drip, d1, and S-1 40mg/m2, twice a day orally, d1~14)34 patients in control group received nedaplatin (80mg/m2, intravenous drip, d1) plus S-1. One cycle of chemotherapy was given every 3 weeks in both groups; 2 cycles of chemotherapy were concurrently given during radiotherapy. The clinical efficacy, survival and adverse reactions were compared between two groups. Results The overall response rates (CR+PR) of observation group and control group were 81.6% and 82.4%,respectively (P>0.05). The 1, 2, 3-year survival rates of observation group and control group were86.8%, 57.9%, 28.9% and 85.3%, 55.9%, 29.4%, respectively (P>0.05). The incidence of peripheral neurotoxicity in observation group was higher than that in control group(P<0.05). There were no significant differences in the incidence of bone marrow suppression,radiation esophagitis, pneumonitis and other adverse reactions between two groups(P >0.05). Conclusion The clinical efficacy and the long-term survival of S-1 plus oxaliplatin and S-1 plus nedaplatin in concurrent chemoradiotherapy are similar for locally advanced ESCC.
Key words:  Esophageal squamous cell carcinoma  Concurrent chemoradiotherapy  S-1  Oxaliplatin  Nedaplatin